Inclusion Criteria:

• Adult patients ≥ 18 years of age
• Clinical diagnosis of acute attack of gout (symptoms: pain, swelling, tenderness, redness or local hyperthermia).
• Acute pain in hand or foot (podagra, chiragra)
• The onset of pain was no more than 2 days ago (e.g., presentation on Monday afternoon, onset of pain on Saturday morning)
• Willingness to participate in the study and ability to give written informed consent.

Exclusion Criteria:

• Known intolerance or contraindication to either medication
• Known intolerance to the placebo (e.g. lactose intolerance).
• Existing (or less than 2 weeks ago) oral treatment with corticosteroids or colchicine.
• Known chronic kidney disease (CKD stage 4 or greater) or an available value of estimated glomerular filtration rate (eGFR) < 30ml/min/1.73 m².
• Known haematopoietic disorder or available values of platelets < 30,000 µl or leucocytes < 4000 µl, or Hb <5 mmol/l/ or 8 g/dl
• Uncontrolled high blood pressure (systolic blood pressure permanently above 160 mmHg).
• Known liver cirrhosis or severe liver disease or available liver enzymes results (ie. Serum Glutamate Oxalate Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase(SGPT)) being elevated by more than twice the respective reference range
• Known current gastric or duodenal ulcer (diagnosed in the last 4 weeks)
• Current chemotherapy or chemotherapy completed less than 3 months ago
• Known HIV infection
• Solid organ transplant with immune suppression
• Desire to have children within the next 6 months in both men and women
• Existing pregnancy or breastfeeding
• Participation in other studies according to the German Medicines Act in the last 3 months
• Participation in the COPAGO study with past gout attack